FDA issued a draft guidance on August 22 detailing the types of modifications it considers suitable for inclusion in a Predetermined Change Control Plan (PCCP) and the information sponsors should include in their premarket approval (PMA), de novo, or 510(k) submissions to support their proposed PCCP.
